BridgeBio Pharma Raises $1 Billion in Equity Financing

BridgeBio Pharma has bolstered its financial standing with a substantial $1 billion investment in convertible preferred equity. This significant capital infusion, led by Sixth Street with participation from HealthCare Royalty (a business of KKR), is earmarked to accelerate the commercialization of its existing therapies and propel the launch of several anticipated new treatments.

The strategic financing positions BridgeBio to capitalize on a critical juncture in its development cycle. With its drug Attruby® demonstrating strong market traction and projected to become a multi-billion dollar product, the company is simultaneously preparing for three additional high-potential U.S. product introductions within the next twelve months. These include BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigratinib for achondroplasia, targeting significant unmet medical needs in rare genetic conditions.

The preferred equity agreement features a 7.00% initial dividend, offering flexibility through payment in kind or cash. Notably, the initial conversion price is set at approximately $137.79 per share, representing a premium exceeding 100% over BridgeBio's 30-day volume-weighted average price. This structure underscores the investors' confidence in the company's future valuation, with the conversion price increasing further after five years. The equity is structured as permanent capital with no maturity date, providing long-term stability.

Sixth Street committed $800 million as the lead investor, while HealthCare Royalty contributed $133.9 million to the initial close of the transaction. This substantial backing from prominent financial institutions highlights the growing investor appetite for well-positioned biopharmaceutical companies with robust pipelines and clear commercialization strategies. The biopharmaceutical sector continues to attract significant investment, driven by advancements in genetic medicine and the increasing demand for novel therapies for rare diseases.

Neil Kumar, Ph.D., Co-Founder and CEO of BridgeBio, emphasized the dual benefit of the funding: ensuring patient access to critical medicines while maximizing economic value for the firm. He stated, "Access to this type and quantum of capital ensures we can deliver on the promise of our launching medicines and beyond." This sentiment was echoed by Jeff Pootoolal, Partner at Sixth Street, who noted their firm's focus on providing flexible, large-scale capital to leading drug developers. Clarke Futch, Chairman and CEO of HealthCare Royalty, also expressed confidence in BridgeBio's management and its ability to bring multiple impactful products to market.

This capital injection arrives at a time when the biopharmaceutical industry is witnessing a surge in funding for companies focused on rare diseases and genetic therapies. The market for such treatments, while niche, offers substantial returns due to high unmet needs and limited competition. BridgeBio's strategy of developing targeted therapies for specific genetic conditions aligns with this trend, positioning it to capture significant market share as its pipeline matures into commercial products.